Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10750646 | 0.95 | POLB (0.40) | POLBKMT2AMEN1USP2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL10748205 | 0.90 | POLB (0.40) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL8083209 | 0.84 | — | — | |
| SCHEMBL6208170 | 0.83 | POLB (0.33) | POLBALDH1A1 | |
| Ethane SCHEMBL1286340 | 0.78 | KMT2A (0.39) | POLBKMT2AALDH1A1MAPT | |
| SCHEMBL15610835 | 0.78 | KMT2A (0.39) | POLBKMT2AALDH1A1MAPT | |
| Toluene SCHEMBL2132068 | 0.77 | POLB (0.49) | POLBL3MBTL1KMT2AMEN1ALDH1A1 | |
| Methane SCHEMBL10572268 | 0.76 | KMT2A (0.38) | KMT2AALDH1A1MAPT | |
| SCHEMBL3182148 | 0.75 | KMT2A (0.41) | POLBKMT2AALDH1A1MAPT | |
| SCHEMBL11434568 | 0.74 | POLB (0.36) | POLBL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008568-A1 | Technetium or rhenium complexes, radiopharmaceutical products comprising them | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008568-A1 | Technetium or rhenium complexes, radiopharmaceutical products comprising them | TSHR, MRPS35, TFRC | POLB 2332/4885L3MBTL1 2221/4885KMT2A 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.